High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development
- PMID: 24356420
- DOI: 10.1158/0008-5472.CAN-13-2921-T
High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development
Abstract
Standardized and reproducible preclinical models that recapitulate the dynamics of prostate cancer are urgently needed. We established a bank of transplantable patient-derived prostate cancer xenografts that capture the biologic and molecular heterogeneity currently confounding prognostication and therapy development. Xenografts preserved the histopathology, genome architecture, and global gene expression of donor tumors. Moreover, their aggressiveness matched patient observations, and their response to androgen withdrawal correlated with tumor subtype. The panel includes the first xenografts generated from needle biopsy tissue obtained at diagnosis. This advance was exploited to generate independent xenografts from different sites of a primary site, enabling functional dissection of tumor heterogeneity. Prolonged exposure of adenocarcinoma xenografts to androgen withdrawal led to castration-resistant prostate cancer, including the first-in-field model of complete transdifferentiation into lethal neuroendocrine prostate cancer. Further analysis of this model supports the hypothesis that neuroendocrine prostate cancer can evolve directly from adenocarcinoma via an adaptive response and yielded a set of genes potentially involved in neuroendocrine transdifferentiation. We predict that these next-generation models will be transformative for advancing mechanistic understanding of disease progression, response to therapy, and personalized oncology.
©2013 AACR.
Similar articles
-
Establishing prostate cancer patient derived xenografts: lessons learned from older studies.Prostate. 2015 May;75(6):628-36. doi: 10.1002/pros.22946. Epub 2015 Jan 5. Prostate. 2015. PMID: 25560784 Free PMC article.
-
A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows anti-tumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions.Prostate. 2008 May 1;68(6):640-50. doi: 10.1002/pros.20728. Prostate. 2008. PMID: 18213631
-
Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.Cancer Res. 2010 Feb 15;70(4):1606-15. doi: 10.1158/0008-5472.CAN-09-2984. Epub 2010 Feb 9. Cancer Res. 2010. PMID: 20145136
-
New models for cancer research: human cancer stem cell xenografts.Curr Opin Pharmacol. 2010 Aug;10(4):380-4. doi: 10.1016/j.coph.2010.05.002. Epub 2010 Jun 17. Curr Opin Pharmacol. 2010. PMID: 20561817 Review.
-
Patient-derived xenografts: A platform for accelerating translational research in prostate cancer.Mol Cell Endocrinol. 2018 Feb 15;462(Pt A):17-24. doi: 10.1016/j.mce.2017.03.013. Epub 2017 Mar 15. Mol Cell Endocrinol. 2018. PMID: 28315377 Review.
Cited by
-
Tumor-agnostic cancer therapy using antibodies targeting oncofetal chondroitin sulfate.Nat Commun. 2024 Aug 30;15(1):7553. doi: 10.1038/s41467-024-51781-0. Nat Commun. 2024. PMID: 39215044 Free PMC article.
-
Bioprinted research models of urological malignancy.Exploration (Beijing). 2024 Feb 20;4(4):20230126. doi: 10.1002/EXP.20230126. eCollection 2024 Aug. Exploration (Beijing). 2024. PMID: 39175884 Free PMC article. Review.
-
Recent advances in lung cancer organoid (tumoroid) research (Review).Exp Ther Med. 2024 Aug 1;28(4):383. doi: 10.3892/etm.2024.12672. eCollection 2024 Oct. Exp Ther Med. 2024. PMID: 39161616 Free PMC article. Review.
-
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer.Nat Rev Urol. 2024 Jul 8. doi: 10.1038/s41585-024-00900-z. Online ahead of print. Nat Rev Urol. 2024. PMID: 38977769 Review.
-
Patient-Derived Conditionally Reprogrammed Cells in Prostate Cancer Research.Cells. 2024 Jun 8;13(12):1005. doi: 10.3390/cells13121005. Cells. 2024. PMID: 38920635 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous